Cytotoxicity against tumor cells

Cytotoxicity against tumor cells refers to the physiological effect of inducing damage or death in malignant cell populations, serving as a primary metric for evaluating anticancer drug efficacy (National Cancer Institute). It is not a discrete molecular entity such as a protein or receptor; rather, it represents a complex phenotypic endpoint often measured in cell-based assays during drug development (ChEMBL Database). This effect can be achieved through various biological mechanisms, including the induction of apoptosis, necrosis, or autophagy (PubMed, PMID: 32623364). Standard chemotherapeutic agents like cisplatin and paclitaxel are characterized by their ability to exert high levels of cytotoxicity through DNA damage or microtubule stabilization (Nature Reviews Drug Discovery). In a clinical and research context, measuring this cytotoxicity helps determine the potency of a compound, although high cytotoxicity is frequently associated with narrow therapeutic windows and adverse effects on healthy, rapidly dividing tissues. Because it describes a physiological outcome rather than a specific protein, it is considered a functional assay target rather than a therapeutic target molecule.

Other names

Tumor cell killingAnticancer cytotoxicityAntineoplastic activityCell-mediated cytotoxicityCellular toxicity

Induction of irreversible cellular damage via multiple pathways including DNA cross-linking, inhibition of topoisomerase, or disruption of the cytoskeleton, ultimately leading to programmed or accidental cell death.